These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 12589849)

  • 1. The effect of recombinant interferon alpha treatment on hearing thresholds in patients with chronic viral hepatitis B.
    Görür K; Kandemir O; Unal M; Ozcan C
    Auris Nasus Larynx; 2003 Feb; 30(1):41-4. PubMed ID: 12589849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha-Interferon for the treatment of idiopathic sudden sensorineural hearing loss.
    Kanemaru S; Fukushima H; Nakamura H; Tamaki H; Fukuyama Y; Tamura Y
    Eur Arch Otorhinolaryngol; 1997; 254(3):158-62. PubMed ID: 9112038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversible bilateral ototoxicity in a patient with chronic hepatitis B during peginterferon alpha-2a treatment.
    Gozdas HT; Karabay O
    Indian J Pharmacol; 2015; 47(1):121-2. PubMed ID: 25821325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of pegylated interferon/lamivudine therapy on auditory functions in patients with chronic hepatitis B.
    Eser Karlidag G; Karlidag T; Demirdag K; Keles E
    Auris Nasus Larynx; 2011 Jun; 38(3):312-8. PubMed ID: 21216118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distortion-product otoacoustic emissions: a useful test for monitoring ototoxicity induced by pegylated interferon and ribavirin treatment in patients with chronic hepatitis C.
    Casale M; Mazzarelli C; Vespasiani Gentilucci U; Potena M; Pappacena M; Faiella F; Galati G; Salvinelli F; Picardi A
    Int J Immunopathol Pharmacol; 2012; 25(2):551-6. PubMed ID: 22697091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of interferon-alpha2b on hearing.
    Kaygusuz I; Oztürk Kaygusuz T; Oztürk A; Kiliç SS; Karlidağ T; Keleş E; Yalçin S
    Int J Audiol; 2004 Sep; 43(8):438-41. PubMed ID: 15643736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversible peg-interferon-induced unilateral sensorineural hearing loss during hepatitis B treatment.
    Salkic N; Zerem E; Zildzic M; Basic M
    Turk J Gastroenterol; 2009 Jun; 20(2):156. PubMed ID: 19530055
    [No Abstract]   [Full Text] [Related]  

  • 8. High dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin with chronic hepatitis C.
    Moskovitz DN; Manoharan P; Heathcote EJ
    Can J Gastroenterol; 2003 Aug; 17(8):479-82. PubMed ID: 12945008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon.
    Oliveri F; Santantonio T; Bellati G; Colombatto P; Mels GC; Carriero L; Dastoli G; Pastore G; Ideo G; Bonino F; Brunetto MR
    Am J Gastroenterol; 1999 May; 94(5):1366-72. PubMed ID: 10235220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axonal neuropathy and hearing loss associated with alpha interferon treatment in chronic hepatitis B: a case report.
    Tunca A; Erbayrak M; Aytaç S; Türkay C
    Turk J Gastroenterol; 2004 Jun; 15(2):97-9. PubMed ID: 15334319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China.
    Zhao H; Kurbanov F; Wan MB; Yin YK; Niu JQ; Hou JL; Wei L; Wang GQ; Tanaka Y; Mizokami M; Si CW
    Clin Infect Dis; 2007 Feb; 44(4):541-8. PubMed ID: 17243057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients.
    Cotonat T; Quiroga JA; López-Alcorocho JM; Clouet R; Pardo M; Manzarbeitia F; Carreño V
    Hepatology; 2000 Feb; 31(2):502-6. PubMed ID: 10655277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-induced sudden hearing loss.
    Kanda Y; Shigeno K; Matsuo H; Yano M; Yamada N; Kumagami H
    Audiology; 1995; 34(2):98-102. PubMed ID: 8561688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retreatment with higher dose interferon alpha in children with chronic hepatitis B infection.
    Ozen H; Koçak N; Yüce A; Gürakan F
    Pediatr Infect Dis J; 1999 Aug; 18(8):694-7. PubMed ID: 10462338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-alpha treatment in children and young adults with chronic hepatitis B: a long-term follow-up study in Taiwan.
    Hsu HY; Tsai HY; Wu TC; Chiang CL; Ni YH; Chen PJ; Chang MH
    Liver Int; 2008 Nov; 28(9):1288-97. PubMed ID: 18397229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon alpha-induced depression in chronic hepatitis C patients: comparison between different types of interferon alpha.
    Malaguarnera M; Di Fazio I; Restuccia S; Pistone G; Ferlito L; Rampello L
    Neuropsychobiology; 1998; 37(2):93-7. PubMed ID: 9566274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial.
    de Niet A; Jansen L; Stelma F; Willemse SB; Kuiken SD; Weijer S; van Nieuwkerk CMJ; Zaaijer HL; Molenkamp R; Takkenberg RB; Koot M; Verheij J; Beuers U; Reesink HW
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):576-584. PubMed ID: 28522204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized controlled trial of sequential pegylated interferon-α and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B.
    Piccolo P; Lenci I; di Paolo D; Demelia L; Sorbello O; Nosotti L; Angelico M
    Antivir Ther; 2013; 18(1):57-64. PubMed ID: 22872648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection.
    Yao GB; Fu XX; Tian GS; Xu DZ; Hao LJ; Huangfu YS; Su CX
    J Gastroenterol Hepatol; 2000 Oct; 15(10):1165-70. PubMed ID: 11106097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective evaluation of dermatological side-effects during alpha-interferon therapy for chronic viral hepatitis.
    Dalekos GN; Christodoulou D; Kistis KG; Zervou EK; Hatzis J; Tsianos EV
    Eur J Gastroenterol Hepatol; 1998 Nov; 10(11):933-9. PubMed ID: 9872615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.